Research analysts at Credit Suisse hoisted their target price on shares of Boston Scientific Corp. (NYSE:BSX) from $11.00 to $12.00 in a report released on Wednesday, AnalystRatingsNetwork reports. Credit Suisse’s target price would indicate a potential upside of 9.79% from the stock’s previous close.
Shares of Boston Scientific Corp. (NYSE:BSX) traded up 0.28% on Wednesday, hitting $10.93. 23,578,662 shares of the company’s stock traded hands. Boston Scientific Corp. has a one year low of $5.04 and a one year high of $11.49. The stock has a 50-day moving average of $10.76 and a 200-day moving average of $8.91. The company’s market cap is $14.678 billion.
Boston Scientific Corp. (NYSE:BSX) last posted its quarterly earnings results on Thursday, July 25th. The company reported $0.18 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.10 by $0.08. The company had revenue of $1.81 billion for the quarter, compared to the consensus estimate of $1.78 billion. During the same quarter last year, the company posted $0.17 earnings per share. Boston Scientific Corp.’s revenue was down 1.0% compared to the same quarter last year. On average, analysts predict that Boston Scientific Corp. will post $0.44 earnings per share for the current fiscal year.
A number of other analysts have also recently weighed in on BSX. Analysts at TheStreet upgraded shares of Boston Scientific Corp. (NYSE:BSX) from a “hold” rating to a “buy” rating in a research note to investors on Tuesday, August 27th. Separately, analysts at Barclays Capital reiterated an “overweight” rating on shares of Boston Scientific Corp. (NYSE:BSX) in a research note to investors on Wednesday, August 14th. They now have a $12.00 price target on the stock. Finally, analysts at Zacks reiterated a “neutral” rating on shares of Boston Scientific Corp. (NYSE:BSX) in a research note to investors on Wednesday, July 31st. They now have a $11.00 price target on the stock.
Fifteen research analysts have rated the stock with a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the stock. Boston Scientific Corp. presently has an average rating of “Hold” and an average target price of $9.53.
In other Boston Scientific Corp. news, CFO Jeffrey Capello unloaded 525,000 shares of Boston Scientific Corp. stock on the open market in a transaction dated Thursday, August 29th. The shares were sold at an average price of $10.68, for a total transaction of $5,607,000.00. Following the completion of the sale, the chief financial officer now directly owns 147,447 shares in the company. The sale was disclosed in a filing with the SEC, which can be accessed through this link.
Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.